Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.

Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA.

Science. 2004 Feb 6;303(5659):844-8. Epub 2004 Jan 2.

2.

Small-molecule inhibitors of the p53-MDM2 interaction.

Vu BT, Vassilev L.

Curr Top Microbiol Immunol. 2011;348:151-72. doi: 10.1007/82_2010_110. Review.

PMID:
21046355
3.

Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.

Shangary S, Wang S.

Annu Rev Pharmacol Toxicol. 2009;49:223-41. doi: 10.1146/annurev.pharmtox.48.113006.094723. Review.

4.

Pharmacologic activation of p53 by small-molecule MDM2 antagonists.

Shen H, Maki CG.

Curr Pharm Des. 2011;17(6):560-8. Review.

5.
6.

Inhibiting the p53-MDM2 interaction: an important target for cancer therapy.

Chène P.

Nat Rev Cancer. 2003 Feb;3(2):102-9. Review.

PMID:
12563309
7.

MDM2 inhibitors for cancer therapy.

Vassilev LT.

Trends Mol Med. 2007 Jan;13(1):23-31. Epub 2006 Nov 28. Review.

PMID:
17126603
8.

Targeting the p53-MDM2 interaction to treat cancer.

Klein C, Vassilev LT.

Br J Cancer. 2004 Oct 18;91(8):1415-9. Review.

9.

Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.

Buolamwini JK, Addo J, Kamath S, Patil S, Mason D, Ores M.

Curr Cancer Drug Targets. 2005 Feb;5(1):57-68. Review.

PMID:
15720190
10.

Small-molecule MDM2-p53 inhibitors: recent advances.

Zhang B, Golding BT, Hardcastle IR.

Future Med Chem. 2015;7(5):631-45. doi: 10.4155/fmc.15.13. Review.

PMID:
25921402
11.

[In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2].

Shinohara T, Uesugi M.

Tanpakushitsu Kakusan Koso. 2007 Oct;52(13 Suppl):1816-7. Review. Japanese. No abstract available.

PMID:
18051440
12.

The structure-based design of Mdm2/Mdmx-p53 inhibitors gets serious.

Popowicz GM, Dömling A, Holak TA.

Angew Chem Int Ed Engl. 2011 Mar 14;50(12):2680-8. doi: 10.1002/anie.201003863. Epub 2011 Feb 21. Review.

13.

Novel cancer therapy by reactivation of the p53 apoptosis pathway.

Bykov VJ, Wiman KG.

Ann Med. 2003;35(7):458-65. Review.

PMID:
14649328
14.

MDM2-p53 interaction in paediatric solid tumours: preclinical rationale, biomarkers and resistance.

Barone G, Tweddle DA, Shohet JM, Chesler L, Moreno L, Pearson AD, Van Maerken T.

Curr Drug Targets. 2014 Jan;15(1):114-23. Review.

PMID:
24387312
15.
16.

The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies.

Secchiero P, di Iasio MG, Gonelli A, Zauli G.

Curr Pharm Des. 2008;14(21):2100-10. Review.

PMID:
18691119
17.

Seeking synergy in p53 transcriptional activation for cancer therapy.

Cheok CF, Lane DP.

Discov Med. 2012 Oct;14(77):263-71. Review.

18.

Small molecule inhibitors of p53/MDM2 interaction.

Fotouhi N, Graves B.

Curr Top Med Chem. 2005;5(2):159-65. Review.

PMID:
15853644
19.

P53 mdm2 inhibitors.

Khoury K, Dömling A.

Curr Pharm Des. 2012;18(30):4668-78. Review.

20.

MDM2 is a central node in the p53 pathway: 12 years and counting.

Bond GL, Hu W, Levine AJ.

Curr Cancer Drug Targets. 2005 Feb;5(1):3-8. Review.

PMID:
15720184

Supplemental Content

Support Center